Table 3.
Best overall response
| Independent radiologist assessment | Investigator assessment | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Nab‐paclitaxel (n = 98) | Docetaxel (n = 99) | P‐value† | Nab‐paclitaxel (n = 98) | Docetaxel (n = 99) | P‐value† | |||||
| n | (%) | n | (%) | n | (%) | n | (%) | |||
| CR | 1 | (1.0) | 1 | (1.0) | 0 | (0.0) | 0 | (0.0) | ||
| PR | 54 | (55.1) | 51 | (51.5) | 60 | (61.2) | 54 | (54.5) | ||
| SD | 36 | (36.7) | 34 | (34.3) | 35 | (35.7) | 34 | (34.3) | ||
| PD | 5 | (5.1) | 7 | (7.1) | 1 | (1.0) | 6 | (6.1) | ||
| NE | 2 | (2.0) | 6 | (6.1) | 2 | (2.0) | 5 | (5.1) | ||
| Overall response rate (CR + PR) | 55 | (56.1) | 52 | (52.5) | 0.669 | 60 | (61.2) | 54 | (54.5) | 0.388 |
| 95% CI (%) | (45.7, 66.1) | (42.2, 62.7) | (50.8, 70.9) | (44.2, 64.6) | ||||||
| Disease‐control rate (CR + PR + SD) | 91 | (92.9) | 86 | (86.9) | 0.238 | 95 | (96.9) | 88 | (88.9) | 0.049 |
| 95% CI (%) | (85.8, 97.1) | (78.6, 92.8) | (91.3, 99.4) | (81.0, 94.3) | ||||||
Analysis set: full analysis set. †Fisher's exact test. CI, confidence interval; CR, complete response; NE, not evaluable; PD, progressive disease; PR, partial response; SD, stable disease.